Pairing an experimental pill with standard chemotherapy shrank tumors or halted growth in most patients with advanced pancreatic cancer , according to early clinical trial results presented Friday at a major international cancer conference.
The findings, shared at the EORTC-NCI-AACR Symposium in Barcelona, come from a phase 1/2 trial testing a daily oral medication called daraxonrasib, along with two standard intravenous chemotherapy drugs , gemcitabine and nab-paclitaxel.
The trial focused on 61 patients whose pancreatic cancer had already spread to other organs and who had not yet received treatment for their advanced disease.
PANCREATIC…
Read the full article at FOXNEWS.COM



